Large chemokine binding spectrum of human and mouse atypical chemokine receptor GPR182 (ACKR5).

ACKR GPCR chemokine receptor binding scavenger

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2023
Historique:
received: 20 09 2023
accepted: 18 10 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

Atypical chemokine receptors (ACKRs) play pivotal roles in immune regulation by binding chemokines and regulating their spatial distribution without inducing G-protein activation. Recently, GPR182, provisionally named ACKR5, was identified as a novel ACKR expressed in microvascular and lymphatic endothelial cells, with functions in hematopoietic stem cell homeostasis. Here, we comprehensively investigated the chemokine binding profile of human and mouse GPR182. Competitive binding assays using flow cytometry revealed that besides CXCL10, CXCL12 and CXCL13, also human and mouse CXCL11, CXCL14 and CCL25, as well as human CCL1, CCL11, CCL19, CCL26, XCL1 and mouse CCL22, CCL24, CCL27 and CCL28 bind with an affinity of less than 100 nM to GPR182. In line with the binding affinity observed

Identifiants

pubmed: 38026988
doi: 10.3389/fphar.2023.1297596
pii: 1297596
pmc: PMC10646305
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1297596

Informations de copyright

Copyright © 2023 Bonnavion, Liu, Kawase, Roquid and Offermanns.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Commun. 2022 Jan 10;13(1):97
pubmed: 35013216
Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):
pubmed: 33875597
Front Immunol. 2016 Jun 10;7:224
pubmed: 27375622
Biochem Biophys Res Commun. 2018 Feb 26;497(1):32-38
pubmed: 29408502
Angiogenesis. 2014 Jul;17(3):511-8
pubmed: 24257808
Front Immunol. 2023 Jul 24;14:1242531
pubmed: 37554323

Auteurs

Remy Bonnavion (R)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Cardiopulmonary Institute, Bad Nauheim, Germany.

Shangmin Liu (S)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.

Haruya Kawase (H)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.

Kenneth Anthony Roquid (KA)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.

Stefan Offermanns (S)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Cardiopulmonary Institute, Bad Nauheim, Germany.
Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt, Germany.
German Center for Cardiovascular Research, Partner Site Frankfurt, Bad Nauheim, Germany.

Classifications MeSH